Cited by 481Immunotherapy and Immune ResponsesImmune responses and vaccinationsHIV Research and Treatment

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Heterologous prime-boost vaccination

Open access

Lu, Shan·2009·Current Opinion in Immunology

DOI 10.1016/j.coi.2009.05.016PMC PMC3743086

Open this paper in CoChat — free account Open PDF

Abstract

An effective vaccine usually requires more than one time immunization in the form of prime-boost. Traditionally the same vaccines are given multiple times as homologous boosts. New findings suggested that prime-boost can be done with different types of vaccines containing the same antigens. In many cases such heterologous prime-boost can be more immunogenic than homologous prime-boost. Heterologous prime-boost represents a new way of immunization and will stimulate better understanding on the immunological basis of vaccines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.coi.2009.05.016

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
Shiver, J. W., Fu, T., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,173
Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine
Amara, R. R. (2001) · Science · doi:10.1126/science.1058915 · Cited by 1,110
The prime-boost strategy: exciting prospects for improved vaccination
Ramshaw, I. A., & Ramsay, A. J. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01612-1 · Cited by 373
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
Girard, M. P., Kiény, M. P., Pinter, A., Barré‐Sinoussi, F., Nara, P. L., Kolbe, H. V. J., Kusumi, K., Chaput, A., Reinhart, T. A., & Muchmore, E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.542 · Cited by 353
Protection of Macaques Against SIV Infection by Subunit Vaccines of SIV Envelope Glycoprotein gp160
Hu, S.-L., Abrams, K., Barber, G. N., Moran, P. A., Zarling, J. M., Langlois, A. J., Kuller, L., Morton, W. R., & Benveniste, R. Ė. (1992) · Science · doi:10.1126/science.1531159 · Cited by 335
Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus
Kent, S. J., Zhao, A., Best, S. J., Chandler, J. D., Boyle, D. B., & Ramshaw, I. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.10180-10188.1998 · Cited by 325
Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen
Hanke, T., Samuel, R. V., Blanchard, T. J., Neumann, V. C., Allen, T. M., Boyson, J. E., Sharpe, S. A., Cook, N. M., Smith, G. L., Watkins, D. I., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7524-7532.1999 · Cited by 304
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
Harari, A., Bart, P., Stöhr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S., Cellerai, C., Erlwein, O. W., Barber, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071331 · Cited by 299
Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides
Emini, E. A., Jameson, B. A., & Wimmer, E. (1983) · Nature · doi:10.1038/304699a0 · Cited by 237
A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS
Zagury, D., Bernard, J., Cheynier, R., Desportes, I., Leonard, R., Fouchard, M., Réveil, B., Ittelé, D., Lurhuma, Z., Mbayo, K., et al. (1988) · Nature · doi:10.1038/332728a0 · Cited by 185

Flagged first, then by citations

Show all 40 references

Sorted by citations

Items 201–300 of 480

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
Das, R., Hyer, R. N., Burton, P. R., Miller, J. M., & Kuter, B. J. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2153532 · Cited by 17
Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections
Koger-Pease, C., Perera, D. J., & Ndao, M. (2023) · Pharmaceuticals · doi:10.3390/ph16030334 · Cited by 18
An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma
Stark, F. C., Weeratna, R. D., Deschatelets, L., Gurnani, K., Dudani, R., McCluskie, M. J., & Krishnan, L. (2017) · Vaccines · doi:10.3390/vaccines5040038 · Cited by 17
Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats
Hummel, J., Bienzle, D., Morrison, A. L., Cieplak, M., Stephenson, K. B., DeLay, J., Woods, J. P., Lichty, B. D., & Bridle, B. W. (2017) · Scientific Reports · doi:10.1038/s41598-017-15992-4 · Cited by 17
Understanding the Determinants of BnAb Induction in Acute HCV Infection
Underwood, A. P., Walker, M. R., Brasher, N. A., Eltahla, A. A., Maher, L., Luciani, F., Lloyd, A. R., & Bull, R. A. (2018) · Viruses · doi:10.3390/v10110659 · Cited by 17
Vaccine against COVID-19
Picazo, J. J. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/085.2021 · Cited by 22
Revival of the heterologous prime‐boost technique in COVID ‐19: An outlook from the history of outbreaks
Siddiqui, A., Adnan, A., Abbas, M., Taseen, S., Ochani, S., & Essar, M. Y. (2022) · Health Science Reports · doi:10.1002/hsr2.531 · Cited by 17
Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidatePreprint
Su, D., Li, X., He, C., Huang, X., Chen, M., Wang, Q., Qin, W., Liang, Y. S., Xu, R., Wu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.16.444369 · Cited by 15
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2
Markewitz, R. D. H., Juhl, D., Pauli, D., Görg, S., Junker, R., Rupp, J., Engel, S., Steinhagen, K., Herbst, V., Zapf, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.811020 · Cited by 14
Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy
Flickinger, J. C., Staudt, R. E., Singh, J., Carlson, R. D., Barton, J. R., Baybutt, T. R., Rappaport, J. A., Zalewski, A., Pattison, A. M., Waldman, S. A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00483-z · Cited by 16
Emerging Cancer Vaccines: The Promise of Genetic Vectors
Aurisicchio, L., & Ciliberto, G. (2011) · Cancers · doi:10.3390/cancers3033687 · Cited by 16
Progress in the development of DNA vaccines against foot-and-mouth disease
Fowler, V. L., & Barnett, P. V. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.198 · Cited by 16
A prime/boost vaccination with HA DNA and Pichia -produced HA protein elicits a strong humoral response in chickens against H5N1
Stachyra, A., Pietrzak, M., Macioła, A. K., Protasiuk, A., Olszewska-Tomczyk, M., Śmietanka, K., Minta, Z., Góra‐Sochacka, A., Kopera, E., & Sirko, A. (2017) · Virus Research · doi:10.1016/j.virusres.2017.01.025 · Cited by 16
J‐LEAPS peptide and LEAPS dendritic cell vaccines
Rosenthal, K. S., Taylor, P. R., & Zimmerman, D. H. (2011) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2011.00278.x · Cited by 16
Protein engineering strategies for the development of viral vaccines and immunotherapeutics
Koellhoffer, J. F., Higgins, C. D., & Lai, J. R. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.10.014 · Cited by 16
Protective Effect of a Prime-Boost Strategy with the Ts87 Vaccine againstTrichinella spiralisInfection in Mice
Gu, Y., Zhan, B., Yang, Y., Yang, X., Zhao, X., Wang, L., Yang, J., Bi, K., Wang, Y., & Zhu, X. (2014) · BioMed Research International · doi:10.1155/2014/326860 · Cited by 16
Technologies for the Development of West Nile Virus Vaccines
Ulbert, S., & Magnusson, S. E. (2014) · Future Microbiology · doi:10.2217/fmb.14.67 · Cited by 15
Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections
Zhang, Y., Guo, X., Guo, M., Chen, X., Li, B., Yu, J., Gu, T., Kong, W., & Wu, Y. (2019) · Immunologic Research · doi:10.1007/s12026-019-09107-6 · Cited by 15
Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
Li, C., Culhane, M. R., Cheeran, M. C. ‐., Pantoja, L. G., Jansen, M. L., Amodie, D., Mellencamp, M. A., & Torremorell, M. (2020) · Veterinary Research · doi:10.1186/s13567-020-00810-z · Cited by 15
Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
Agrati, C., Capone, S., Castilletti, C., Cimini, E., Matusali, G., Meschi, S., Tartaglia, E., Camerini, R., Lanini, S., Milleri, S., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00394-5 · Cited by 15
Potential threat of human pathogenic orthopoxviruses to public health and control strategies
Zhang, Y., Zhou, Y., Pei, R., Chen, X., & Wang, Y. (2023) · Journal of Biosafety and Biosecurity · doi:10.1016/j.jobb.2022.12.004 · Cited by 15
Developments in virus-like particle-based vaccines for HIV
Buonaguro, L., Tagliamonte, M., Visciano, M. L., Tornesello, M. L., & Buonaguro, F. M. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.152 · Cited by 15
Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model
Simons, B. W., Cannella, F., Rowley, D., & Viscidi, R. P. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02493-z · Cited by 15
Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches
Scotti, N., Buonaguro, L., Tornesello, M. L., Cardi, T., & Buonaguro, L. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.79 · Cited by 15
Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques
Yu, J., Thomas, P. V., Sciacca, M., Wu, C., Liu, J., He, X., Miller, J. J., Hachmann, N. P., Surve, N., McMahan, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101018 · Cited by 14
Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice
Li, D., Bian, L., Cui, L., Zhou, J., Li, G., Zhao, X., Xing, L., Cui, J., Sun, B., Jiang, C., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s464720 · Cited by 14
Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice
Le, L., Zhang, W., Karmakar, S., Ahmad, G., Torben, W., & Siddiqui, A. A. (2014) · Parasitology Research · doi:10.1007/s00436-014-3757-4 · Cited by 14
A heterologous ‘prime‐boost’ anti‐PEDV immunization for pregnant sows protects neonatal piglets through lactogenic immunity against PEDV
Wen, Z., Xu, Z., Zhou, Q., Li, W., Wu, Y., Du, Y., Chen, L., Xue, C., & Cao, Y. (2019) · Letters in Applied Microbiology · doi:10.1111/lam.13197 · Cited by 14
Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen
Haq, K., Jia, Y., Elahi, S. M., MacLean, S., Akache, B., Gurnani, K., Chattopadhyay, A., Nazemi-Moghaddam, N., Gilbert, R., McCluskie, M. J., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.08.079 · Cited by 14
Xyloglucan based mucosal nanovaccine for immunological protection against brucellosis developed by supercritical fluid technology
Vyas, S., Dhoble, S., Ghodake, V. N., & Patravale, V. B. (2020) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2020.100053 · Cited by 14
Mucosal Immunization Induces a Higher Level of Lasting Neutralizing Antibody Response in Mice by a Replication‐Competent Smallpox Vaccine: Vaccinia Tiantan Strain
Lu, B., Yu, W., Huang, X., Wang, H., Liu, L., & Chen, Z. (2011) · BioMed Research International · doi:10.1155/2011/970424 · Cited by 14
Preclinical vaccines against mammary carcinoma
Lollini, P., Cavallo, F., Giovanni, C. D., & Nanni, P. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.845530 · Cited by 14
Antibody responses to prime–boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140
Emmer, K. L., Wieczorek, L., Tuyishime, S., Molnar, S., Polonis, V. R., & Ertl, H. C. J. (2016) · AIDS · doi:10.1097/qad.0000000000001224 · Cited by 14
Evaluation of protective efficacy induced by different heterologous prime-boost strategies encoding triosephosphate isomerase against Schistosoma japonicum in mice
Dai, Y., Song, Z., Tang, J., Xing, Y., Qu, G., Dai, J., Jin, X., & Wang, X. (2017) · Parasites & Vectors · doi:10.1186/s13071-017-2036-5 · Cited by 14
Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse
Guo, Q., Wang, L., Xu, P., Geng, F., Guo, J., Dong, L., Bao, X., Zhou, Y., Feng, M., Wu, J., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1841392 · Cited by 14
Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques
McCracken, M. K., Kuklis, C. H., Kannadka, C. B., Barvir, D. A., Sanborn, M. A., Waickman, A. T., Siegfried, H., Victor, K., Hatch, K., Barrera, R. A. D. L., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00339-y · Cited by 14
A heterologous virus-vectored vaccine for prevention of Middle East respiratory syndrome induces long protective immune response against MERS-CoV
Kovyrshina, A. V., Federal Research Centre of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, M. O. H. O. T. R. F., Dolzhikova, I. V., Federal Research Centre of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, M. O. H. O. T. R. F., Grousova, D. M., Federal Research Centre of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, M. O. H. O. T. R. F., Balyasin, M. V., Federal Research Centre of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, M. O. H. O. T. R. F., Botikov, A. G., Federal Research Centre of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, M. O. H. O. T. R. F., et al. (2020) · Immunologiya · doi:10.33029/0206-4952-2020-41-2-135-143 · Cited by 13
The potential of adenoviral vaccine vectors with altered antigen presentation capabilities
Neukirch, L., Fougeroux, C. E., Andersson, A.-M. C., & Holst, P. J. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1711054 · Cited by 13
A Live-Attenuated Zika Virus Vaccine with High Production Capacity Confers Effective Protection in Neonatal Mice
Ye, X., Liu, X., Shu, T., Deng, W., Liao, M., Zheng, Y., Zheng, X., Zhang, X., Li, T., Fan, W., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00383-21 · Cited by 13
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates
Walters, J. N., Schouest, B., Patel, A. R., Reuschel, E. L., Schultheis, K., Parzych, E. M., Maricic, I., Gary, E. N., Purwar, M., Andrade, V. M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.060 · Cited by 14
A Self-Help Program for Memory CD8+ T Cells: Positive Feedback via CD40-CD40L Signaling as a Critical Determinant of Secondary Expansion
Shugart, J., Bambina, S., Alice, A. F., Montler, R. D., & Bahjat, K. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064878 · Cited by 13
Enhancement of Protective Efficacy through Adenoviral Vectored Vaccine Priming and Protein Boosting Strategy Encoding Triosephosphate Isomerase (SjTPI) against Schistosoma japonicum in Mice
Dai, Y., Wang, X., Tang, J., Song, Z., Xing, Y., Dai, J., Jin, X., & Zhu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120792 · Cited by 13
Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine
Li, W., Wang, S., & Lu, S. (2013) · Vaccines · doi:10.3390/vaccines2010036 · Cited by 13
Self-citation
Evaluation of the immune response elicited by vaccination with viral vectors encoding FMDV capsid proteins and boosted with inactivated virus
Romanutti, C., D’Antuono, A., Palacios, C., Quattrocchi, V., Zamorano, P. I., TORRE, J. L. L., & Mattion, N. (2013) · Veterinary Microbiology · doi:10.1016/j.vetmic.2013.04.017 · Cited by 13
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
Bendjama, K., & Quéméneur, É. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1334746 · Cited by 14
A Review of UK-Registered and Candidate Vaccines for Bovine Respiratory Disease
Lemon, J. L., & McMenamy, M. J. (2021) · Vaccines · doi:10.3390/vaccines9121403 · Cited by 12
Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice
Beicht, J., Kubinski, M., Zdora, I., Puff, C., Biermann, J., Gerlach, T. H., Baumgärtner, W., Sutter, G., Osterhaus, A. D. M. E., Prajeeth, C. K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1177324 · Cited by 12
Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2
Nguyen, K. G., Mantooth, S. M., Vrabel, M. R., & Zaharoff, D. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.858904 · Cited by 14
Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
Chu, C., Schönbrunn, A., Fischer, D., Liu, Y., Hocher, J.-G., Weinerth, J., Klemm, K., von Baehr, V., Krämer, B. K., Elitok, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1187880 · Cited by 13
CTLA4 mediated targeting enhances immunogenicity against PRRSV in a DNA prime/killed virus boost strategy
Wang, Y., Zhao, H., Ma, Z., Wang, Y., & Feng, W.-H. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.05.008 · Cited by 12
Prime-Boost Immunization Using a DNA Vaccine Delivered by Attenuated Salmonella enterica Serovar Typhimurium and a Killed Vaccine Completely Protects Chickens from H5N1 Highly Pathogenic Avian Influenza Virus
Pan, Z., Zhang, X., Geng, S., Fang, Q., You, M., Zhang, L., Jiao, X., & Liu, X. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00387-09 · Cited by 12
DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses
Liu, W., Wong, Y. C., Chen, S. M. Y., Tang, J., Wang, H., Cheung, A. K. L., & Chen, Z. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.06.047 · Cited by 11
Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity
Bot, A. I., Qiu, Z., Wong, R. M. H., Obrocea, M., & Smith, K. A. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-132 · Cited by 12
In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant
Heinen, N., Marheinecke, C. S., Bessen, C., Blazquez‐Navarro, A., Roch, T., Stervbo, U., Anft, M., Plaza‐Sirvent, C., Buße, S., Klöhn, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1062210 · Cited by 10
Evaluation of bovine respiratory syncytial virus (BRSV) and bovine herpesvirus (BHV) specific antibody responses between heterologous and homologous prime-boost vaccinated western Canadian beef calves.
Erickson, N., Berenik, A., Lardner, H. A., Lacoste, S. R., Campbell, J., Gow, S., Waldner, C., & Ellis, J. (2021) · PubMed Central · Cited by 11
Production and Evaluation of Chicken Egg Yolk Immunoglobulin (IgY) against Human and Simian Rotaviruses
de Vasconcelos, G. A. L. B. M., Lanzarini, N. M., Guimarães, J. R., Heinemann, M. B., Volotão, E. D. M., da Silva, A. D. S., Heneine, L. G. D., de Oliveira, J. M., & Pinto, M. A. (2022) · Viruses · doi:10.3390/v14091995 · Cited by 11
Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project
Collatuzzo, G., Lodi, V., Feola, D., Palma, G. D., Sansone, E., Sala, E., Janke, C., Castelletti, N., Porru, S., Spiteri, G., et al. (2022) · Viruses · doi:10.3390/v14122657 · Cited by 11
A DNA Prime and MVA Boost Strategy Provides a Robust Immunity against Infectious Bronchitis Virus in Chickens
Chandrasekar, S., Kingstad-Bakke, B. A., Wu, C., Phanse, Y., Osorio, J. E., & Talaat, A. M. (2023) · Vaccines · doi:10.3390/vaccines11020302 · Cited by 11
Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model
Bourgine, M., Dion, S., Godon, O., Guillén, G. E., Michel, M., & Aguilar, J. C. (2012) · Virology · doi:10.1016/j.virol.2012.04.007 · Cited by 11
Considerations for Clinical Translation of MG1 Maraba Virus
Breitbach, C. J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9794-7_19 · Cited by 11
Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses
Amaral, M. P., Coirada, F. C., Apostólico, J. D. S., Tomita, N., Fernandes, E. R., Souza, H. F. S., Chura‐Chambi, R. M., Morganti, L., Boscardin, S. B., & Rosa, D. S. (2021) · Current Research in Immunology · doi:10.1016/j.crimmu.2021.03.001 · Cited by 12
Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein
Vassell, R. A., He, Y., Vennakalanti, P., Dey, A., Zhuang, M., Wang, W., Sun, Y., Biron‐Sorek, Z., Srivastava, I. K., LaBranche, C. C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128562 · Cited by 11
The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors
Kamel, M. S., Munds, R. A., & Verma, M. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216112 · Cited by 10
Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy
Delgado-Almenta, V., Blaya-Cánovas, J. L., Calahorra, J., López-Tejada, A., Griñán‐Lisón, C., & Granados-Principal, S. M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020216 · Cited by 10
Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review
Houlder, E. L., da Silva, L. F., van Diepen, A., Amaral, M. S., Wilson, R. A., Hokke, C. H., Roestenberg, M., & Bakker, W. A. M. (2025) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012956 · Cited by 11
Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses
Zhang, L., Jia, N., Li, J., Han, Y., Cao, W., Wang, S., Huang, Z., & Lu, S. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28795 · Cited by 10
Self-citation
Biomaterials at the interface of nano- and micro-scale vector–cellular interactions in genetic vaccine design
Jones, C. H., Håkansson, A., & Pfeifer, B. A. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb01058b · Cited by 10
Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV
Wang, S., Yates, N. L., Pollara, J., Voronin, Y., Stanfield-Oakley, S., Han, D. G., Hu, G., Li, W., Ferrari, G., Tomaras, G. D., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00441-9 · Cited by 10
Self-citation
Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
Pan, Y., Jia, R., Li, J., Wang, M., Chen, S., Liu, M., Zhu, D., Zhao, X., Wu, Y., Yang, Q., et al. (2020) · Virology Journal · doi:10.1186/s12985-020-01334-w · Cited by 10
Profiling Humoral Immunity After Mixing and Matching COVID-19 Vaccines Using SARS-CoV-2 Variant Protein Microarrays
Kuo, H., Kuo, K.-C., Du, P.-X., Keskin, B. B., Su, W., Ho, T., Tsai, P.-S., Pau, C. H., Shih, H.-C., Huang, Y., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100507 · Cited by 12
Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
Wang, S., Chou, T.-H. W., Hackett, A., Efros, V., Wang, Y., Han, D. G., Wallace, A., Chen, Y., Hu, G., Liu, S., et al. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1380137 · Cited by 10
Self-citation
Identifying Key Drivers of Efficient B Cell Responses: On the Role of T Help, Antigen-Organization, and Toll-like Receptor Stimulation for Generating a Neutralizing Anti-Dengue Virus Response
Sobczak, J. M., Barkovska, I., Baļķe, I., Rothen, D. A., Mohsen, M. O., Skrastiņa, D., Ogrina, A., Martina, B. E. E., Jansons, J., Bogans, J., et al. (2024) · Vaccines · doi:10.3390/vaccines12060661 · Cited by 9
Protection of chicks from Newcastle disease by combined vaccination with a plasmid DNA and the pre-fusion protein of the virulent genotype VII of Newcastle disease virus
Sun, J., Han, Z., Zhao, R., Ai, H., Chen, L., Li, L., & Liu, S. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.039 · Cited by 9
Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing
Jaishwal, P., Jha, K., & Singh, S. P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134012 · Cited by 10
Enhancement of humoral and cellular immunity in chickens against reticuloendotheliosis virus by DNA prime-protein boost vaccination
Li, K., Gao, H., Gao, L., Qi, X., Gao, Y., Qin, L., Wang, Y., & Wang, X. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.010 · Cited by 9
Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
Jordan, I., Lohr, V., Genzel, Y., Reichl, U., & Sandig, V. (2013) · Microorganisms · doi:10.3390/microorganisms1010100 · Cited by 9
Induction of a Robust Humoral Response using HIV-1 VLPMPER-V3as a Novel Candidate Vaccine in BALB/c Mice
Tohidi, F., Sadat, S. M., Bolhassani, A., Yaghobi, R., & Larijani, M. S. (2019) · Current HIV Research · doi:10.2174/1570162x17666190306124218 · Cited by 9
Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine
Thiel, N., Selwyn, C., Murphy, G. A. V., Simpson, S., & Chakrabarti, A. C. (2021) · npj Vaccines · doi:10.1038/s41541-021-00325-4 · Cited by 9
Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination
Bauswein, M., Peterhoff, D., Plentz, A., Hiergeist, A., Wagner, R., Gessner, A., Salzberger, B., Schmidt, B., & Bauernfeind, S. (2022) · iScience · doi:10.1016/j.isci.2021.103694 · Cited by 9
Highly potent delivery method of gp160 envelope vaccine combining lentivirus-like particles and DNA electrotransfer
Vandermeulen, G., Athanasopoulos, T., Trundley, A., Foster, K., Véronique Préat, A., Yáñez‐Muñoz, R. J., & Dickson, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.035 · Cited by 9
Human immunodeficiency virus vaccines
Girard, M. P., & Koff, W. C. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50054-4 · Cited by 9
Tuberculosis vaccination sequence effect on protection in wild boar
Díez‐Delgado, I., Sevilla, I. A., Garrido, J. M., Romero, B., Geijó, M., Domı́nguez, L., Juste, R. A., Aranaz, A., de la Fuente, J., & Gortázar, C. (2019) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2019.101329 · Cited by 9
A Comparative Analysis of Clinical Stage 3 COVID-19 Vaccines using Knowledge RepresentationPreprint
Burgos-Salcedo, J. D. (2021) · medRxiv · doi:10.1101/2021.03.07.21253082 · Cited by 8
Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus
Lamrayah, M., Charriaud, F., Desmares, M., Coiffier, C., Mégy, S., Colomb, E., Terreux, R., Lucifora, J., Durantel, D., & Verrier, B. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105483 · Cited by 8
Advances in Chlamydia trachomatis Vaccination: Unveiling the Potential of Major Outer Membrane Protein Derivative Constructs
Kiekens, C., Morré, S. A., & Vanrompay, D. C. G. (2024) · Microorganisms · doi:10.3390/microorganisms12061196 · Cited by 8
Vaccination Strategies: Mixing Paths Versus Matching Tracks
Livieratos, A., Gogos, C. A., Θωμάς, Ι., & Akinosoglou, K. (2025) · Vaccines · doi:10.3390/vaccines13030308 · Cited by 8
Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy
Rios, A. V., Metko, M. M., Tonne, J. M., Thompson, J., Kendall, B., Chen, A., Mudrick, H. E., Masopust, D., Irshad, S., Barry, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.023 · Cited by 8
Clostridium perfringens beta toxin DNA prime-protein boost elicits enhanced protective immune response in mice
Solanki, A. K., Bhatia, B., Kaushik, H., Deshmukh, S. K., Dixit, A., & Garg, L. C. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-017-8333-2 · Cited by 8
Interleukin-21 enhances the antibody avidity elicited by DNA prime and MVA boost vaccine
Fan, W., Wan, Y., & Li, Q. (2019) · Cytokine · doi:10.1016/j.cyto.2019.154814 · Cited by 8
Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations
Greter, H., Ivol, S., Mathieu, V. O., Erismann, S., Prytherch, H., & Steinmann, P. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.12.003 · Cited by 8
Different dendritic cells-based vaccine constructs influence HIV-1 antigen-specific immunological responses and cytokine generation in virion-exposed splenocytes
Milani, A., Agi, E., Pouriayevali, M. H., Motamedi‐Rad, M., Motevalli, F., & Bolhassani, A. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109406 · Cited by 8
Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
Zhang, J., He, Q., Yan, X., Liu, J., Bai, Y., An, C., Cui, B., Gao, F., Mao, Q., Wang, J., et al. (2022) · MedComm · doi:10.1002/mco2.188 · Cited by 7
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant
Pastore, G., Polvere, J., Fiorino, F., Lucchesi, S., Montesi, G., Rancan, I., Zirpoli, S., Lippi, A., Durante, M., Fabbiani, M., et al. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2333952 · Cited by 8
Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime–boost vaccination against cancer
Dai, M., Vassaux, G., Xu, M., You, R.-I., Hsieh, Y.-F., Ouisse, L., Lo, K.-Y., Sytwu, H., & Chao, T.-Y. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.09.001 · Cited by 8
Heterologous prime-boost immunization with live SPY1 and DnaJ protein of Streptococcus pneumoniae induces strong Th1 and Th17 cellular immune responses in mice
Qiu, Y., Zhang, X., Wang, H., Zhang, X., Mo, Y., Sun, X., Wang, J., Yin, Y., & Xu, W. (2017) · The Journal of Microbiology · doi:10.1007/s12275-017-7262-1 · Cited by 8
Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia
Santi, T., Sungono, V., Kamarga, L., Samakto, B. D., Hidayat, F., Hidayat, F. K., Satolom, M., Permana, A., Yusuf, I., Suriapranata, I. M., et al. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.2.209 · Cited by 8
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN
Yu, J., Thomas, P. V., McMahan, K., Jacob-Dolan, C., Liu, J., He, X., Hope, D. L., Martinez, E. J., Chen, W., Sciacca, M., et al. (2022) · Science Advances · doi:10.1126/sciadv.ade4433 · Cited by 8
Two is better than one
Lu, S. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70256-0 · Cited by 8
Self-citation
Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain
Bissa, M., Pacchioni, S. M., Zanotto, C., Morghen, C. D. G., Illiano, E., Granucci, F., Zanoni, I., Broggi, A., & Radaelli, A. (2013) · Virus Research · doi:10.1016/j.virusres.2013.09.016 · Cited by 8
Evaluation of multivalent H2 influenza pandemic vaccines in mice
Lenny, B. J., Sonnberg, S., Danner, A. F., Friedman, K., Webby, R. J., Webster, R. G., & Jones, J. C. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.01.026 · Cited by 8

Authors: Lu, S.
Affiliations: Jiangsu Province Hospital (CN)
Corresponding author: Lu, Shan
ORCID: Lu, Shan
Venue: Current Opinion in Immunology
Publisher: Elsevier BV
Published: 2009-06
Volume: 21
Issue: 3
Pages: 346-351
ISSN: 0952-7915 (ISSN-L)
DOI: 10.1016/j.coi.2009.05.016
PMC: PMC3743086
OpenAlex: W1979742563
Cited by: 481
References: 40
Citations by year: 2026: 15 · 2025: 25 · 2024: 21 · 2023: 32 · 2022: 66 · 2021: 53 · 2020: 41 · 2019: 28 · 2018: 17 · 2017: 27 · 2016: 13 · 2015: 18 · 2014: 21 · 2013: 34 · 2012: 18
FWCI: 1.81
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Current Opinion in Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Institute of Allergy and Infectious Diseases (P01AI082274, R01AI065250, R01 AI06250, U19AI082676)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: heterologous prime-boost, prime-boost vaccination, vaccine immunogenicity, vaccine adjuvants
MeSH terms: Animals, Humans, Immunization, Secondary, Neoplasms, Research, Research Design, Vaccination, HIV Infections, AIDS Vaccines, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Heterologous prime-boost vaccination

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks